# Developing a U.S. National Cohort to Improve Virologic Suppression among Stimulant-using Men Living with HIV.

> **NIH NIH UG3** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $1,054,387

## Abstract

PROJECT SUMMARY/ ABSTRACT
 A resurgent stimulant epidemic among sexual minority men/men who have sex with men, including those
living with HIV, could compromise the U.S. Ending the HIV Epidemic goals by interfering with HIV care
engagement, adherence, and virologic suppression among sexual minority men living with HIV. Prominent
multi-level barriers interfere with HIV virologic suppression among sexual minority men living with HIV,
particularly among those who use stimulants.
 We will digitally recruit at least 1,000 sexual minority men living with HIV, of whom at least 40% will identify
as Black/African-American and at least 70% will have active stimulant use to identify multi-level determinants
of HIV care engagement, adherence, and virologic suppression among sexual minority men living with HIV,
with and without stimulant use. Guided by the social ecological model, we will investigate network factors (HIV
status, stimulant use), geospatial determinants (background stimulant use prevalence, EHE region), and other
structural factors (intersectional stigma, structural racism) that affect virologic suppression (Aim 1). After
recruitment milestones are met, we will perform a nested randomized clinical trial to test a multi-component
intervention to improve virologic suppression, adherence, positive affect, and stimulant use among sexual
minority men living with HIV who use stimulants (n=300). The intervention, known as reSTART, will combine
an evidence-based positive affect intervention delivered through a smartphone app and use of urine point-of-
care testing to perform adherence self-monitoring, with motivational messages to improve or maintain
adherence delivered via the reSTART app (Aim 2). In Aim 3 of the proposal, we will assess the impact of
reSTART on incremental cost per person on virologic suppression and optimal antiretroviral therapy adherence
measured via hair tenofovir levels.
 By this high-impact study’s end, we will have identified multi-level determinants of the treatment continuum
among digitally-recruited sexual minority men living with HIV, including among those who use stimulants; and
the impact of a multi-component reSTART mHealth intervention using novel point-of-care adherence self-
monitoring on HIV virologic suppression, adherence, and cost among a key underserved population.

## Key facts

- **NIH application ID:** 10675863
- **Project number:** 1UG3DA058304-01
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Adam Wayne Carrico
- **Activity code:** UG3 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $1,054,387
- **Award type:** 1
- **Project period:** 2023-05-15 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10675863

## Citation

> US National Institutes of Health, RePORTER application 10675863, Developing a U.S. National Cohort to Improve Virologic Suppression among Stimulant-using Men Living with HIV. (1UG3DA058304-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10675863. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*